Nonmuscle Myosin Type IIA
Nonmuscle Myosin Type IIB
Myosins
Myosin Type IV
Myosin Type II
Myosin Heavy Chains
Myosin Type III
Heterocyclic Compounds with 4 or More Rings
Myosin Type I
Myosin Light Chains
Myosin Type V
Myosin Subfragments
Molecular Motor Proteins
Sodium-Phosphate Cotransporter Proteins, Type IIa
Actins
Actomyosin
Myosin-Light-Chain Kinase
Protein Isoforms
Group II Phospholipases A2
Myosin-Light-Chain Phosphatase
Muscle, Striated
Sodium-Phosphate Cotransporter Proteins
Molecular Sequence Data
Amino Acid Sequence
Actin Cytoskeleton
Prolyl-Hydroxylase Inhibitors
Cytoskeleton
rho-Associated Kinases
Tropomyosin
Abundant expression of myosin heavy-chain IIB RNA in a subset of human masseter muscle fibres. (1/187)
Type IIB fast fibres are typically demonstrated in human skeletal muscle by histochemical staining for the ATPase activity of myosin heavy-chain (MyHC) isoforms. However, the monoclonal antibody specific for the mammalian IIB isoform does not detect MyHC IIB protein in man and MyHC IIX RNA is found in histochemically identified IIB fibres, suggesting that the IIB protein isoform may not be present in man; if this is not so, jaw-closing muscles, which express a diversity of isoforms, are likely candidates for their presence. ATPase histochemistry, immunohistochemistry polyacrylamide gel electrophoresis and in situ hybridization, which included a MyHC IIB-specific mRNA riboprobe, were used to compare the composition and RNA expression of MyHC isoforms in a human jaw-closing muscle, the masseter, an upper limb muscle, the triceps, an abdominal muscle, the external oblique, and a lower limb muscle, the gastrocnemius. The external oblique contained a mixture of histochemically defined type I, IIA and IIB fibres distributed in a mosaic pattern, while the triceps and gastrocnemius contained only type I and IIA fibres. Typical of limb muscle fibres, the MyHC I-specific mRNA probes hybridized with histochemically defined type I fibres, the IIA-specific probes with type IIA fibres and the IIX-specific probes with type IIB fibres. The MyHC IIB mRNA probe hybridized only with a few histochemically defined type I fibres in the sample from the external oblique; in addition to this IIB message, these fibres also expressed RNAs for MyHC I, IIA and IIX. MyHC IIB RNA was abundantly expressed in histochemical and immunohistochemical type IIA fibres of the masseter, together with transcripts for IIA and in some cases IIX. No MyHC IIB protein was detected in fibres and extracts of either the external oblique or masseter by immunohistochemistry, immunoblotting and electrophoresis. Thus, IIB RNA, but not protein, was found in the fibres of two different human skeletal muscles. It is believed this is the first report of the substantial expression of IIB mRNA in man as demonstrated in a subset of masseter fibres, but rarely in limb muscle, and in only a few fibres of the external oblique. These findings provide further evidence for the complexity of myosin gene expression, especially in jaw-closing muscles. (+info)Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes. (2/187)
May-Hegglin anomaly (MHA) and Fechtner (FTNS) and Sebastian (SBS) syndromes are autosomal dominant platelet disorders that share macrothrombocytopenia and characteristic leukocyte inclusions. FTNS has the additional clinical features of nephritis, deafness, and cataracts. Previously, mutations in the nonmuscle myosin heavy chain 9 gene (MYH9), which encodes nonmuscle myosin heavy chain IIA (MYHIIA), were identified in all three disorders. The spectrum of mutations and the genotype-phenotype and structure-function relationships in a large cohort of affected individuals (n=27) has now been examined. Moreover, it is demonstrated that MYH9 mutations also result in two other FTNS-like macrothrombocytopenia syndromes: Epstein syndrome (EPS) and Alport syndrome with macrothrombocytopenia (APSM). In all five disorders, MYH9 mutations were identified in 20/27 (74%) affected individuals. Four mutations, R702C, D1424N, E1841K, and R1933X, were most frequent. R702C and R702H mutations were only associated with FTNS, EPS, or APSM, thus defining a region of MYHIIA critical in the combined pathogenesis of macrothrombocytopenia, nephritis, and deafness. The E1841K, D1424N, and R1933X coiled-coil domain mutations were common to both MHA and FTNS. Haplotype analysis using three novel microsatellite markers revealed that three E1841K carriers--one with MHA and two with FTNS--shared a common haplotype around the MYH9 gene, suggesting a common ancestor. The two new globular-head mutations, K371N and R702H, as well as the recently identified MYH9 mutation, R705H, which results in DFNA17, were modeled on the basis of X-ray crystallographic data. Altogether, our data suggest that MHA, SBS, FTNS, EPS, and APSM comprise a phenotypic spectrum of disorders, all caused by MYH9 mutations. On the basis of our genetic analyses, the name "MYHIIA syndrome" is proposed to encompass all of these disorders. (+info)Modulation of myosin A expression by a newly established tetracycline repressor-based inducible system in Toxoplasma gondii. (3/187)
We have developed a control system for regulating gene activation in Toxoplasma gondii. The elements of this system are derived from the Escherichia coli tetracycline resistance operon, which has been widely used to tightly control gene expression in eukaryotes. The tetracycline repressor (tetR) interferes with transcription initiation while the chimeric transactivator, composed of the tetR fused to the activating domain of VP16 transcriptional factor, allows tet-dependent transcription. Accordingly, tetracycline derivatives such as anhydrotetracycline, which we found to be well tolerated by T.gondii, can serve as effector molecules, allowing control of gene expression in a reversible manner. As a prerequisite to functionally express the tetR in T.gondii, we used a synthetic gene with change of codon frequency. Whereas no activation of transcription was achieved using the synthetic tetracycline-controlled transactivator, tTA2(s), the TetR(s )modulates parasite transcription over a range of approximately 15-fold as measured for several reporter genes. We show here that the tetR-dependent induction of the T.gondii myosin A transgene expression drastically down-regulates the level of endogenous MyoA. This myosin is under the control of a tight feedback mechanism, which occurs at the protein level. (+info)Differential localization of non-muscle myosin II isoforms and phosphorylated regulatory light chains in human MRC-5 fibroblasts. (4/187)
We investigated the localization of non-muscle myosin II isoforms and mono- (at serine 19) and diphosphorylated (at serine 19 and threonine 18) regulatory light chains (RLCs) in motile and non-motile MRC-5 fibroblasts. In migrating cells, myosin IIA localized to the lamella and throughout the posterior region. Myosin IIB colocalized with myosin IIA to the posterior region except at the very end. Diphosphorylated RLCs were detected in the restricted region where myosin IIA was enriched. In non-motile cells, myosin IIA was enriched in peripheral stress fibers with diphosphorylated RLCs, but myosin IIB was not. Our results suggest that myosin IIA may be highly activated by diphosphorylation of RLCs and primarily involved in cell migration. (+info)Evidence of a role for nonmuscle myosin II in herpes simplex virus type 1 egress. (5/187)
After cell entry, herpes simplex virus (HSV) particles are transported through the host cell cytoplasm to nuclear pores. Following replication, newly synthesized virus particles are transported back to the cell periphery via a complex pathway including a cytoplasmic phase involving some form of unenveloped particle. These various transport processes are likely to make use of one or more components of the cellular cytoskeletal systems and associated motor proteins. Here we report that the HSV type 1 (HSV-1) major tegument protein, VP22, interacts with the actin-associated motor protein nonmuscle myosin IIA (NMIIA). HSV-1 infection resulted in reorganization of NMIIA, inducing retraction of NMIIA from the cell periphery and condensation into a spoke-like distribution around the nucleus along with a second effect of accumulation in a perinuclear cluster. VP22 did not appear to colocalize with the reorganized cagelike distribution of NMIIA. However, VP22 has been previously reported to localize in a perinuclear vesicular pattern, and significant overlap was observed between this pattern and the perinuclear clusters of NMIIA. Inhibition of the ATPase activity of NMIIA with the myosin-specific inhibitor butanedione monoxime impaired the formation of the perinuclear vesicular VP22 accumulations and also the release of virus into the extracellular medium while having much less effect on the yield of cell-associated virus. Virus infection frequently results in the induction of highly extended processes emanating from the infected cell, and we observed that VP22-containing particles line up along NMIIA-containing filaments which run through these protrusions. (+info)Toxoplasma gondii myosin A and its light chain: a fast, single-headed, plus-end-directed motor. (6/187)
Successful host cell invasion is a prerequisite for survival of the obligate intracellular apicomplexan parasites and establishment of infection. Toxoplasma gondii penetrates host cells by an active process involving its own actomyosin system and which is distinct from induced phagocytosis. Toxoplasma gondii myosin A (TgMyoA) is presumed to achieve power gliding motion and host cell penetration by the capping of apically released adhesins towards the rear of the parasite. We report here an extensive biochemical characterization of the functional TgMyoA motor complex. TgMyoA is anchored at the plasma membrane and binds a novel type of myosin light chain (TgMLC1). Despite some unusual features, the kinetic and mechanical properties of TgMyoA are unexpectedly similar to those of fast skeletal muscle myosins. Microneedle-laser trap and sliding velocity assays established that TgMyoA moves in unitary steps of 5.3 nm with a velocity of 5.2 microm/s towards the plus end of actin filaments. TgMyoA is the first fast, single-headed myosin and fulfils all the requirements for power parasite gliding. (+info)Defective expression of GPIb/IX/V complex in platelets from patients with May-Hegglin anomaly and Sebastian syndrome. (7/187)
BACKGROUND AND OBJECTIVES: May-Hegglin anomaly (MHA) and Sebastian syndrome (SBS) are inherited macrothrombocytopenias with D hle-like bodies in leukocytes. MHA-SBS are due to mutations of the gene (MYH9) for the heavy chain of non-muscle myosin IIA (NMMHC-IIA), the only myosin II expressed in platelets. The bleeding tendency is often more severe than expected on the basis of platelet count, but no abnormality of platelet function has been identified. To characterize platelet abnormalities deriving from MYH9 mutations better, we studied surface glycoproteins (GPs) in platelets from MHA-SBS patients. DESIGN AND METHODS: Eight patients from 4 unrelated families were studied. Platelet surface GPs were studied by flow cytometry in both the whole platelet population and subpopulations of platelets identified according to their size. RESULTS: Flow cytometry identified a defect of the GPIb/IX/V complex in the whole platelet population in 7 of 8 patients. Moreover, in all patients the subpopulation of large platelets had defective expression of this complex. INTERPRETATION AND CONCLUSIONS: These findings indicate that MYH9 mutations may be responsible for reduced surface expression of GPIb/IX/V. This defect could contribute to the bleeding tendency of these patients. The identification of a GPIb/IX/V defect in MHA-SBS platelets raises the question of the differential diagnosis from heterozygous Bernard-Soulier syndrome. (+info)Mutations in human nonmuscle myosin IIA found in patients with May-Hegglin anomaly and Fechtner syndrome result in impaired enzymatic function. (8/187)
A family of autosomal-dominant diseases including May-Hegglin anomaly, Fechtner syndrome, Sebastian syndrome, Alport syndrome, and Epstein syndrome are commonly characterized by giant platelets and thrombocytopenia. In addition, there may be leukocyte inclusions, deafness, cataracts, and nephritis, depending on the syndrome. Mutations in the human nonmuscle myosin IIA heavy chain gene (MYH9) have been linked to these diseases. Two of the recently described mutations, N93K and R702C, are conserved in smooth and nonmuscle myosins from vertebrates and lie in the head domain of myosin. Interestingly, the two mutations lie within close proximity in the three-dimensional structure of myosin. These two mutations were engineered into a heavy meromyosin-like recombinant fragment of nonmuscle myosin IIA, which was expressed in baculovirus along with the appropriate light chains. The R702C mutant displays 25% of the maximal MgATPase activity of wild type heavy meromyosin and moves actin filaments at half the wild type rate. The effects of the N93K mutation are more dramatic. This heavy meromyosin has only 4% of the maximal MgATPase activity of wild type and does not translocate actin filaments in an in vitro motility assay. Biochemical characterization of the mutant is consistent with this mutant being unable to fully adopt the "on" conformation. (+info)Nonmuscle Myosin Type IIA (NMIIA) is a type of non-muscle myosin protein that belongs to the myosin II family. These motor proteins are responsible for generating contractile forces in non-muscle cells, which allows them to change shape and move. NMIIA is widely expressed in various tissues and plays crucial roles in numerous cellular processes, including cytokinesis (cell division), maintenance of cell shape, and intracellular transport.
NMIIA consists of two heavy chains, two regulatory light chains, and two essential light chains. The heavy chains have a motor domain that binds to actin filaments and hydrolyzes ATP to generate force for movement along the actin filament. The regulatory and essential light chains regulate the activity and assembly of NMIIA.
Mutations in the gene encoding NMIIA (MYH9) have been associated with several human genetic disorders, such as May-Hegglin anomaly, Fechtner syndrome, and Delletten-Patterson syndrome, which are characterized by thrombocytopenia, bleeding disorders, and hearing loss.
Nonmuscle Myosin Type IIB (NMMIIB) is a type of motor protein that belongs to the myosin superfamily. It is involved in various cellular processes, including cell division, adhesion, migration, and maintenance of cell shape. NMMIIB is composed of two heavy chains, two regulatory light chains, and two essential light chains. The heavy chains have a motor domain that enables the protein to move along actin filaments, generating force and movement.
NMMIIB is widely expressed in non-muscle tissues, and its activity is regulated by phosphorylation and dephosphorylation of the regulatory light chains. Phosphorylation activates NMMIIB, leading to contractile forces that can alter cell shape and promote cell motility. In contrast, dephosphorylation inactivates NMMIIB, allowing for relaxation of the contractile forces.
Abnormal regulation of NMMIIB has been implicated in various pathological conditions, including cancer metastasis, cardiovascular diseases, and neurological disorders. Therefore, understanding the molecular mechanisms that regulate NMMIIB function is an important area of research with potential therapeutic implications.
Myosins are a large family of motor proteins that play a crucial role in various cellular processes, including muscle contraction and intracellular transport. They consist of heavy chains, which contain the motor domain responsible for generating force and motion, and light chains, which regulate the activity of the myosin. Based on their structural and functional differences, myosins are classified into over 35 classes, with classes II, V, and VI being the most well-studied.
Class II myosins, also known as conventional myosins, are responsible for muscle contraction in skeletal, cardiac, and smooth muscles. They form filaments called thick filaments, which interact with actin filaments to generate force and movement during muscle contraction.
Class V myosins, also known as unconventional myosins, are involved in intracellular transport and organelle positioning. They have a long tail that can bind to various cargoes, such as vesicles, mitochondria, and nuclei, and a motor domain that moves along actin filaments to transport the cargoes to their destinations.
Class VI myosins are also unconventional myosins involved in intracellular transport and organelle positioning. They have two heads connected by a coiled-coil tail, which can bind to various cargoes. Class VI myosins move along actin filaments in a unique hand-over-hand motion, allowing them to transport their cargoes efficiently.
Overall, myosins are essential for many cellular functions and have been implicated in various diseases, including cardiovascular diseases, neurological disorders, and cancer.
Myosin type IV, also known as myosin-1c, is a member of the unconventional myosin family. It is an actin-based molecular motor protein that plays a role in intracellular transport, organelle positioning, and cell signaling. Myosin-1c has a single head domain, which can bind to actin filaments and hydrolyze ATP to generate force and motion. It is widely expressed in various tissues, including the heart, skeletal muscle, and brain. Mutations in the gene that encodes myosin-1c have been associated with several human diseases, such as deafness, cardiomyopathy, and neurological disorders.
Myosin Type II, also known as myosin II or heavy meromyosin, is a type of motor protein involved in muscle contraction and other cellular movements. It is a hexameric protein composed of two heavy chains and four light chains. The heavy chains have a head domain that binds to actin filaments and an tail domain that forms a coiled-coil structure, allowing the formation of filaments. Myosin II uses the energy from ATP hydrolysis to move along actin filaments, generating force and causing muscle contraction or other cell movements. It plays a crucial role in various cellular processes such as cytokinesis, cell motility, and maintenance of cell shape.
Myosin Heavy Chains are the large, essential components of myosin molecules, which are responsible for the molecular motility in muscle cells. These heavy chains have a molecular weight of approximately 200 kDa and form the motor domain of myosin, which binds to actin filaments and hydrolyzes ATP to generate force and movement during muscle contraction. There are several different types of myosin heavy chains, each with specific roles in various tissues and cellular functions. In skeletal and cardiac muscles, for example, myosin heavy chains have distinct isoforms that contribute to the contractile properties of these tissues.
Myosin III is a type of molecular motor protein found in cells, responsible for providing cellular movement and organization. More specifically, Myosin III is involved in the regulation of actin filament dynamics and contributes to various cellular functions such as vesicle transport, maintenance of cell shape, and signal transduction.
Myosin III has a unique motor domain that allows it to move along actin filaments while generating force. It also contains a protein kinase domain, which enables it to phosphorylate target proteins and regulate their activity. Mutations in the MYO3 gene have been associated with certain inherited diseases, such as Usher syndrome type 1F, a condition characterized by hearing loss and retinitis pigmentosa, leading to vision loss.
Heterocyclic compounds with 4 or more rings refer to a class of organic compounds that contain at least four aromatic or non-aromatic rings in their structure, where one or more of the rings contains atoms other than carbon (heteroatoms) such as nitrogen, oxygen, sulfur, or selenium. These compounds are widely found in nature and have significant importance in medicinal chemistry due to their diverse biological activities. Many natural and synthetic drugs, pigments, vitamins, and antibiotics contain heterocyclic structures with four or more rings. The properties of these compounds depend on the size, shape, and nature of the rings, as well as the presence and position of functional groups.
Myosin Type I, also known as myosin-IA, is a type of motor protein found in non-muscle cells. It is involved in various cellular processes such as organelle transport, cell division, and maintenance of cell shape. Myosin-IA consists of a heavy chain, light chains, and a cargo-binding tail domain. The heavy chain contains the motor domain that binds to actin filaments and hydrolyzes ATP to generate force and movement along the actin filament.
Myosin-I is unique among myosins because it can move in both directions along the actin filament, whereas most other myosins can only move in one direction. Additionally, myosin-I has a high duty ratio, meaning that it spends a larger proportion of its ATP hydrolysis cycle bound to the actin filament, making it well-suited for processes requiring sustained force generation or precise positioning.
Myosin light chains are regulatory proteins that bind to the myosin head region of myosin molecules, which are involved in muscle contraction. There are two types of myosin light chains, essential and regulatory, that have different functions. The essential light chains are necessary for the assembly and stability of the myosin filaments, while the regulatory light chains control the calcium-sensitive activation of the myosin ATPase activity during muscle contraction. Phosphorylation of the regulatory light chains plays a critical role in regulating muscle contraction and relaxation.
Myosin Type V is an molecular motor protein involved in the intracellular transport of various cargoes, including vesicles and organelles. It belongs to the family of myosins, which are actin-based motors that convert chemical energy into mechanical work through the hydrolysis of ATP.
Myosin V is characterized by its long tail domain, which allows it to form dimers or higher-order oligomers, and its head domain, which binds to actin filaments and hydrolyzes ATP to generate force and movement. The protein moves in a hand-over-hand manner along the actin filament, allowing it to transport cargoes over long distances within the cell.
Myosin V has been implicated in various cellular processes, including exocytosis, endocytosis, and organelle positioning. Mutations in the MYO5A gene, which encodes Myosin Type V, have been associated with several human genetic disorders, such as Griscelli syndrome type 1 and familial progressive arthro-ophthalmopathy.
Myosin subfragments refer to the smaller components that result from the dissociation or proteolytic digestion of myosin, a motor protein involved in muscle contraction. The two main subfragments are called S1 and S2.
S1 is the "head" of the myosin molecule, which contains the actin-binding site, ATPase activity, and the ability to generate force and motion during muscle contraction. It has a molecular weight of approximately 120 kDa.
S2 is the "tail" of the myosin molecule, which has a molecular weight of about 350 kDa and is responsible for forming the backbone of the thick filament in muscle sarcomeres. S2 can be further divided into light meromyosin (LMM) and heavy meromyosin (HMM). HMM consists of S1 and part of S2, while LMM comprises the remaining portion of S2.
These subfragments are essential for understanding myosin's structure, function, and interactions with other muscle components at a molecular level.
Molecular motor proteins are a type of protein that convert chemical energy into mechanical work at the molecular level. They play a crucial role in various cellular processes, such as cell division, muscle contraction, and intracellular transport. There are several types of molecular motor proteins, including myosin, kinesin, and dynein.
Myosin is responsible for muscle contraction and movement along actin filaments in the cytoplasm. Kinesin and dynein are involved in intracellular transport along microtubules, moving cargo such as vesicles, organelles, and mRNA to various destinations within the cell.
These motor proteins move in a stepwise fashion, with each step driven by the hydrolysis of adenosine triphosphate (ATP) into adenosine diphosphate (ADP) and inorganic phosphate (Pi). The directionality and speed of movement are determined by the structure and regulation of the motor proteins, as well as the properties of the tracks along which they move.
Sodium-phosphate cotransporter proteins, type IIa (NaPi-IIa), are a subtype of membrane transport proteins that facilitate the active transport of sodium and phosphate ions across the cell membrane. They play a crucial role in maintaining phosphate homeostasis within the body by regulating the reabsorption of phosphate in the kidney's proximal tubules.
NaPi-IIa proteins are located on the brush border membrane of the proximal tubule cells and function to couple the movement of sodium ions down its electrochemical gradient into the cell with the influx of phosphate ions against its concentration gradient, from the lumen into the cell. This process is driven by the sodium-potassium ATPase pump, which maintains a low intracellular sodium concentration and a negative membrane potential.
NaPi-IIa proteins are encoded by the SLC34A1 gene in humans and are subject to regulation by various hormonal and physiological factors, such as parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), and dietary phosphate intake. Dysregulation of NaPi-IIa function has been implicated in several kidney diseases and disorders of phosphate homeostasis, such as hyperphosphatemia and hypophosphatemic rickets.
Actin is a type of protein that forms part of the contractile apparatus in muscle cells, and is also found in various other cell types. It is a globular protein that polymerizes to form long filaments, which are important for many cellular processes such as cell division, cell motility, and the maintenance of cell shape. In muscle cells, actin filaments interact with another type of protein called myosin to enable muscle contraction. Actins can be further divided into different subtypes, including alpha-actin, beta-actin, and gamma-actin, which have distinct functions and expression patterns in the body.
Actomyosin is a contractile protein complex that consists of actin and myosin filaments. It plays an essential role in muscle contraction, cell motility, and cytokinesis (the process of cell division where the cytoplasm is divided into two daughter cells). The interaction between actin and myosin generates force and movement through a mechanism called sliding filament theory. In this process, myosin heads bind to actin filaments and then undergo a power stroke, which results in the sliding of one filament relative to the other and ultimately leads to muscle contraction or cellular movements. Actomyosin complexes are also involved in various non-muscle cellular processes such as cytoplasmic streaming, intracellular transport, and maintenance of cell shape.
Myosin-Light-Chain Kinase (MLCK) is an enzyme that plays a crucial role in muscle contraction. It phosphorylates the regulatory light chains of myosin, a protein involved in muscle contraction, leading to the activation of myosin and the initiation of the contractile process. MLCK is activated by calcium ions and calmodulin, and its activity is essential for various cellular processes, including cytokinesis, cell motility, and maintenance of cell shape. In addition to its role in muscle contraction, MLCK has been implicated in several pathological conditions, such as hypertension, atherosclerosis, and cancer.
Protein isoforms are different forms or variants of a protein that are produced from a single gene through the process of alternative splicing, where different exons (or parts of exons) are included in the mature mRNA molecule. This results in the production of multiple, slightly different proteins that share a common core structure but have distinct sequences and functions. Protein isoforms can also arise from genetic variations such as single nucleotide polymorphisms or mutations that alter the protein-coding sequence of a gene. These differences in protein sequence can affect the stability, localization, activity, or interaction partners of the protein isoform, leading to functional diversity and specialization within cells and organisms.
Group II Phospholipases A2 (PLA2) are a class of enzymes that hydrolyze the sn-2 ester bond of glycerophospholipids to release free fatty acids and lysophospholipids. They are classified as one of the several groups of PLA2 based on their structure, function, and calcium dependence.
Group II PLA2s are secreted enzymes that require millimolar concentrations of calcium ions for their activity. They consist of a single polypeptide chain with a molecular weight ranging from 14 to 18 kDa. These enzymes play important roles in various biological processes, including inflammation, host defense, and lipid metabolism. Dysregulation of Group II PLA2 activity has been implicated in several pathological conditions, such as atherosclerosis, arthritis, and neurodegenerative diseases.
A muscle is a soft tissue in our body that contracts to produce force and motion. It is composed mainly of specialized cells called muscle fibers, which are bound together by connective tissue. There are three types of muscles: skeletal (voluntary), smooth (involuntary), and cardiac. Skeletal muscles attach to bones and help in movement, while smooth muscles are found within the walls of organs and blood vessels, helping with functions like digestion and circulation. Cardiac muscle is the specific type that makes up the heart, allowing it to pump blood throughout the body.
Myosin-Light-Chain Phosphatase (MLCP) is an enzyme complex that plays a crucial role in the regulation of muscle contraction and relaxation. It is responsible for dephosphorylating the myosin light chains, which are key regulatory components of the contractile apparatus in muscles.
The phosphorylation state of the myosin light chains regulates the interaction between actin and myosin filaments, which is necessary for muscle contraction. When the myosin light chains are phosphorylated, they bind more strongly to actin, leading to increased contractile force. Conversely, when the myosin light chains are dephosphorylated by MLCP, the interaction between actin and myosin is weakened, allowing for muscle relaxation.
MLCP is composed of three subunits: a catalytic subunit (PP1cδ), a regulatory subunit (MYPT1), and a small subunit (M20). The regulatory subunit contains binding sites for various signaling molecules that can modulate the activity of MLCP, such as calcium/calmodulin, protein kinase C, and Rho-associated protein kinase (ROCK). Dysregulation of MLCP has been implicated in various muscle disorders, including hypertrophic cardiomyopathy, dilated cardiomyopathy, and muscle atrophy.
Striated muscle, also known as skeletal or voluntary muscle, is a type of muscle tissue that is characterized by the presence of distinct light and dark bands, or striations, when viewed under a microscope. These striations correspond to the arrangement of sarcomeres, which are the functional units of muscle fibers.
Striated muscle is under voluntary control, meaning that it is consciously activated by signals from the nervous system. It is attached to bones via tendons and is responsible for producing movements of the body. Striated muscle fibers are multinucleated, meaning that they contain many nuclei, and are composed of numerous myofibrils, which are rope-like structures that run the length of the fiber.
The myofibrils are composed of thick and thin filaments that slide past each other to cause muscle contraction. The thick filaments are made up of the protein myosin, while the thin filaments are composed of actin, tropomyosin, and troponin. When a nerve impulse arrives at the muscle fiber, it triggers the release of calcium ions from the sarcoplasmic reticulum, which bind to troponin and cause a conformational change that exposes the binding sites on actin for myosin. The myosin heads then bind to the actin filaments and pull them towards the center of the sarcomere, causing the muscle fiber to shorten and contract.
Sodium-phosphate cotransporter proteins are membrane transport proteins that facilitate the active transport of sodium and inorganic phosphate ions across biological membranes. These proteins play a crucial role in maintaining phosphate homeostasis within the body by regulating the absorption and excretion of phosphate in the kidneys and intestines. They exist in two major types, type I (NaPi-I) and type II (NaPi-II), each having multiple subtypes with distinct tissue distributions and regulatory mechanisms.
Type I sodium-phosphate cotransporters are primarily expressed in the kidney's proximal tubules and play a significant role in reabsorbing phosphate from the primary urine back into the bloodstream. Type II sodium-phosphate cotransporters, on the other hand, are found in both the kidneys and intestines. In the kidneys, they contribute to phosphate reabsorption, while in the intestines, they facilitate phosphate absorption from food.
These proteins function by coupling the passive downhill movement of sodium ions (driven by the electrochemical gradient) with the active uphill transport of phosphate ions against their concentration gradient. This coupled transport process enables cells to maintain intracellular phosphate concentrations within a narrow range, despite fluctuations in dietary intake and renal function.
Dysregulation of sodium-phosphate cotransporter proteins has been implicated in various pathological conditions, such as chronic kidney disease (CKD), tumoral calcinosis, and certain genetic disorders affecting phosphate homeostasis.
Molecular sequence data refers to the specific arrangement of molecules, most commonly nucleotides in DNA or RNA, or amino acids in proteins, that make up a biological macromolecule. This data is generated through laboratory techniques such as sequencing, and provides information about the exact order of the constituent molecules. This data is crucial in various fields of biology, including genetics, evolution, and molecular biology, allowing for comparisons between different organisms, identification of genetic variations, and studies of gene function and regulation.
An amino acid sequence is the specific order of amino acids in a protein or peptide molecule, formed by the linking of the amino group (-NH2) of one amino acid to the carboxyl group (-COOH) of another amino acid through a peptide bond. The sequence is determined by the genetic code and is unique to each type of protein or peptide. It plays a crucial role in determining the three-dimensional structure and function of proteins.
The actin cytoskeleton is a complex, dynamic network of filamentous (threadlike) proteins that provides structural support and shape to cells, allows for cell movement and division, and plays a role in intracellular transport. Actin filaments are composed of actin monomers that polymerize to form long, thin fibers. These filaments can be organized into different structures, such as stress fibers, which provide tension and support, or lamellipodia and filopodia, which are involved in cell motility. The actin cytoskeleton is constantly remodeling in response to various intracellular and extracellular signals, allowing for changes in cell shape and behavior.
Prolyl-hydroxylase inhibitors (PHI) are a class of pharmaceutical compounds that function as inhibitors of prolyl-hydroxylase enzymes. These enzymes play a crucial role in the regulation of hypoxia-inducible factors (HIF), which are transcription factors that respond to changes in oxygen levels in the body.
Under normal conditions, prolyl-hydroxylase enzymes hydroxylate specific residues on HIF proteins, leading to their degradation by other proteins. However, when oxygen levels are low (hypoxia), these enzymes become less active, allowing HIF proteins to accumulate and activate genes that help the body adapt to low-oxygen conditions.
PHIs work by inhibiting prolyl-hydroxylase enzymes, which in turn leads to an increase in HIF protein levels and activation of HIF-dependent genes. This effect can be useful in treating certain medical conditions, such as anemia associated with chronic kidney disease (CKD). In CKD, the kidneys are unable to produce enough erythropoietin, a hormone that stimulates red blood cell production. By increasing HIF protein levels, PHIs can stimulate the production of erythropoietin and improve anemia symptoms in patients with CKD.
Examples of PHIs include roxadustat, vadadustat, and daprodustat, which are currently under investigation for the treatment of anemia associated with CKD.
The cytoskeleton is a complex network of various protein filaments that provides structural support, shape, and stability to the cell. It plays a crucial role in maintaining cellular integrity, intracellular organization, and enabling cell movement. The cytoskeleton is composed of three major types of protein fibers: microfilaments (actin filaments), intermediate filaments, and microtubules. These filaments work together to provide mechanical support, participate in cell division, intracellular transport, and help maintain the cell's architecture. The dynamic nature of the cytoskeleton allows cells to adapt to changing environmental conditions and respond to various stimuli.
Rho-associated kinases (ROCKs) are serine/threonine kinases that are involved in the regulation of various cellular processes, including actin cytoskeleton organization, cell migration, and gene expression. They are named after their association with the small GTPase RhoA, which activates them upon binding.
ROCKs exist as two isoforms, ROCK1 and ROCK2, which share a high degree of sequence homology and have similar functions. They contain several functional domains, including a kinase domain, a coiled-coil region that mediates protein-protein interactions, and a Rho-binding domain (RBD) that binds to active RhoA.
Once activated by RhoA, ROCKs phosphorylate a variety of downstream targets, including myosin light chain (MLC), LIM kinase (LIMK), and moesin, leading to the regulation of actomyosin contractility, stress fiber formation, and focal adhesion turnover. Dysregulation of ROCK signaling has been implicated in various pathological conditions, such as cancer, cardiovascular diseases, neurological disorders, and fibrosis. Therefore, ROCKs have emerged as promising therapeutic targets for the treatment of these diseases.
Cardiac myosins are a type of myosin protein that are specifically expressed in the cardiac muscle cells (or cardiomyocytes) of the heart. These proteins play a crucial role in the contraction and relaxation of heart muscles, which is essential for proper heart function and blood circulation.
Myosins are molecular motors that use chemical energy from ATP to generate force and movement. In the context of cardiac muscle cells, cardiac myosins interact with another protein called actin to form sarcomeres, which are the basic contractile units of muscle fibers. During contraction, the heads of cardiac myosin molecules bind to actin filaments and pull them together, causing the muscle fiber to shorten and generate force.
There are different isoforms of cardiac myosins that can vary in their structure and function. Mutations in the genes encoding these proteins have been linked to various forms of cardiomyopathy, which are diseases of the heart muscle that can lead to heart failure and other complications. Therefore, understanding the structure and function of cardiac myosins is an important area of research for developing therapies and treatments for heart disease.
Tropomyosin is a protein that plays a crucial role in muscle contraction. It is a long, thin filamentous protein that runs along the length of actin filaments in muscle cells, forming part of the troponin-tropomyosin complex. This complex regulates the interaction between actin and myosin, which are the other two key proteins involved in muscle contraction.
In a relaxed muscle, tropomyosin blocks the myosin-binding sites on actin, preventing muscle contraction from occurring. When a signal is received to contract, calcium ions are released into the muscle cell, which binds to troponin and causes a conformational change that moves tropomyosin out of the way, exposing the myosin-binding sites on actin. This allows myosin to bind to actin and generate force, leading to muscle contraction.
Tropomyosin is composed of two alpha-helical chains that wind around each other in a coiled-coil structure. There are several isoforms of tropomyosin found in different types of muscle cells, including skeletal, cardiac, and smooth muscle. Mutations in the genes encoding tropomyosin have been associated with various inherited muscle disorders, such as hypertrophic cardiomyopathy and distal arthrogryposis.
Cytokinesis is the part of the cell division process (mitosis or meiosis) in which the cytoplasm of a single eukaryotic cell divides into two daughter cells. It usually begins after telophase, and it involves the constriction of a contractile ring composed of actin filaments and myosin motor proteins that forms at the equatorial plane of the cell. This results in the formation of a cleavage furrow, which deepens and eventually leads to the physical separation of the two daughter cells. Cytokinesis is essential for cell reproduction and growth in multicellular organisms, and its failure can lead to various developmental abnormalities or diseases.